X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - New Drug Applications - 01/Jul 06:07

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company has completed the submission...

Articles similaires

Sorry! Image not available at this time

Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis

drugs.com - 09/Sep 08:09

GAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage...

Sorry! Image not available at this time

Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?

zacks.com - 06/Sep 15:31

SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sorry! Image not available at this time

Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?

zacks.com - 06/Sep 15:31

SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sorry! Image not available at this time

Aethlon Medical to Present at the Life Sciences Investor Forum September 19th

financialpost.com - 13/Sep 12:38

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...

Sorry! Image not available at this time

Aethlon Medical to Present at the Life Sciences Investor Forum September 19th

financialpost.com - 13/Sep 12:38

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...

Sorry! Image not available at this time

Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington's Disease

drugs.com - 14/Sep 05:09

LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological...

Sorry! Image not available at this time

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

menafocus.qa - 13/Sep 07:04

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical...

Sorry! Image not available at this time

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

pressarabia.qa - 13/Sep 07:04

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical...

Sorry! Image not available at this time

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

pressarabia.qa - 13/Sep 07:04

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical...

Sorry! Image not available at this time

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

arabnewsnetwork.ps - 13/Sep 07:04

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical...

Les derniers communiqués